MCL‐R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R‐CHOP / R‐HAD) AND a RITUXIMAB‐LENALIDOMIDE MAINTENANCE. (June 2017) - Ribrag, V.; Feugier, P.; Doorduijn, J.; Delfau‐Larue, M.; Hermine, O.; Kluin‐Nelemans, H.; Dasilva, M.; Lopez‐Hernandez, A.; Walewski, J.; Szymczyk, M.; Pott, C.; Homburg, C.; et al.